Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Patient selection for cytoreductive nephrectomy

Anil Kapoor • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Sunitinib
CARMENA

Anil Kapoor, MD, FRCSC, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada, outlines the importance of careful patient selection for cytoreductive nephrectomy, referencing the CARMENA trial (NCT00930033), which tests the benefit of nephrectomy compared to sunitinib. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals